Aquatic Capital Management LLC Has $7.57 Million Holdings in Moderna, Inc. (NASDAQ:MRNA)

Aquatic Capital Management LLC trimmed its stake in shares of Moderna, Inc. (NASDAQ:MRNA - Free Report) by 34.9% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 181,982 shares of the company's stock after selling 97,418 shares during the quarter. Aquatic Capital Management LLC's holdings in Moderna were worth $7,567,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds also recently added to or reduced their stakes in the company. Norges Bank acquired a new position in Moderna during the fourth quarter worth $163,833,000. FMR LLC raised its holdings in Moderna by 7.4% during the fourth quarter. FMR LLC now owns 18,664,634 shares of the company's stock worth $776,075,000 after purchasing an additional 1,282,469 shares during the last quarter. Pictet Asset Management Holding SA raised its holdings in Moderna by 170.5% during the fourth quarter. Pictet Asset Management Holding SA now owns 1,766,398 shares of the company's stock worth $73,447,000 after purchasing an additional 1,113,455 shares during the last quarter. Invesco Ltd. raised its holdings in Moderna by 24.3% during the fourth quarter. Invesco Ltd. now owns 5,006,462 shares of the company's stock worth $208,169,000 after purchasing an additional 979,858 shares during the last quarter. Finally, Renaissance Technologies LLC raised its holdings in Moderna by 225.7% during the fourth quarter. Renaissance Technologies LLC now owns 1,010,758 shares of the company's stock worth $42,027,000 after purchasing an additional 700,458 shares during the last quarter. 75.33% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

MRNA has been the topic of several recent research reports. William Blair restated a "market perform" rating on shares of Moderna in a research report on Thursday, April 17th. UBS Group reduced their target price on shares of Moderna from $96.00 to $78.00 and set a "buy" rating on the stock in a report on Wednesday, February 19th. Evercore ISI set a $50.00 target price on shares of Moderna in a report on Friday, February 14th. Berenberg Bank upped their target price on shares of Moderna from $33.00 to $42.00 and gave the company a "hold" rating in a report on Thursday, January 16th. Finally, Leerink Partners reduced their target price on shares of Moderna from $31.00 to $27.00 and set an "underweight" rating on the stock in a report on Thursday, January 16th. Four equities research analysts have rated the stock with a sell rating, sixteen have given a hold rating, three have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of "Hold" and a consensus target price of $58.70.

Moderna Stock Up 1.3 %

Shares of NASDAQ MRNA traded up $0.36 during trading hours on Tuesday, hitting $27.82. The company had a trading volume of 5,238,914 shares, compared to its average volume of 7,367,871. The stock has a market capitalization of $10.76 billion, a P/E ratio of -3.00 and a beta of 2.23. The firm's 50 day moving average is $30.03 and its 200-day moving average is $38.15. Moderna, Inc. has a 1-year low of $23.15 and a 1-year high of $170.47.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.